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Synopsis 12 
Diagnostic uncertainty and a high prevalence of viral infections present unique challenges for 13 
antimicrobial prescribing for respiratory tract infections (RTIs). Procalcitonin (PCT) has been 14 
shown to support prescribing decisions and reduce antimicrobial use safely in patients with RTIs but 15 
recent study results have been variable. 16 
Methods 17 
We conducted a feasibility study of the introduction of PCT testing in patients admitted to hospital 18 
with a lower RTI to determine if PCT testing is an effective and worthwhile intervention to introduce 19 
to support the existing AMS programme and safely decrease antimicrobial prescribing in patients 20 
admitted with RTIs.  21 
Results 22 
A total of 79 patients were randomised to the intervention PCT guided treatment group and 40 23 
patients to the standard care respiratory control group. 24 
The addition of PCT testing led to a significant decrease in duration of antimicrobial 25 
prescriptions (mean 6.8 versus 8.9 days p=0.012) and decreased length of hospital stay (median 26 
7 versus 8 days, p=0.009) between the PCT and respiratory control group. PCT did not demonstrate 27 
a significant reduction in antimicrobial consumption when measured as DDDs and days of 28 
therapy. 29 
Conclusions 30 
PCT testing had a positive effect on antimicrobial prescribing during this feasibility study. The 31 
successful implementation of PCT testing in a randomised controlled trial requires an ongoing 32 
comprehensive education programme, greater integration into the AMS programme and delivery of 33 
PCT results in a timely manner. This feasibility study has shown that a larger randomised controlled 34 
trial would be beneficial to further explore the positive aspects of these findings.    35 
 36 
Introduction  37 
Antimicrobial resistance (AMR) is a major risk to public health globally that leads to increasing 38 
healthcare costs, treatment failure, and increased morbidity and mortality.1-3 There is a strong 39 
association between sub-optimal antimicrobial prescribing and AMR.4 To optimise prescribing, 40 
hospital antimicrobial stewardship (AMS) programmes should target areas of high antimicrobial 41 
prescribing. One such area is respiratory tract infections (RTIs). Shorter antimicrobial courses offer one 42 
potential solution to the overuse of antimicrobials for RTIs5 and there is evidence to support such 43 
strategies6 7 even in severe hospital infections.8  44 
Diagnostic uncertainty and a high prevalence of viral infections present unique challenges for 45 
antimicrobial prescribing for RTIs.9-12 This contributes to over-use and/or sub-optimal use of 46 
antimicrobials13 14 for RTIs such as community acquired pneumonia (CAP), including prolonged 47 
treatment courses of up to 11 days,15 without a correlation between duration of treatment and 48 
infection severity.15 16 Physicians are often reluctant to shorten antimicrobial course durations due to 49 
the fear of incomplete pathogen eradication which could potentially lead to relapse and associated 50 
morbidity and mortality.6 There is also a high rate of antimicrobial continuation where viral 51 
infections,17 including influenza,18 are identified due to overriding concerns about secondary bacterial 52 
infections. However, a recent study has shown a bacterial co-infection rate of only 40%.11  53 
To address these issues, there is a growing interest in the use of novel diagnostic techniques and 54 
biomarkers as an AMS tool.19 It is important that AMS programmes investigate the opportunity 55 
afforded by these new techniques and the potential they offer to optimise antimicrobial treatment 56 
more promptly20 and change prescribing behaviour.21 Procalcitonin (PCT) testing is one such diagnostic 57 
technique. PCT is a peptide precursor to the hormone calcitonin. It is usually undetected but is 58 
upregulated in response to a bacterial infection following stimulation of bacterial-induced cytokines.22 59 
Upregulation of PCT is blocked in viral infections due to the release of the cytokine interferon gamma, 60 
resulting in a higher specificity of PCT to distinguish between bacterial and viral infections when 61 
compared to other inflammatory markers such as CRP.23 PCT levels decrease rapidly when patients 62 
are recovering from infection.24 Hence it offers the potential to support clinical decision making for 63 
the initiation and discontinuation of antimicrobials in patients with a clinical suspicion of a bacterial 64 
infection when considered along with the clinical assessment of the patients. PCT has been shown to 65 
support prescribing decisions and reduce antimicrobial use safely in patients with RTIs25-28 but findings 66 
from recent studies have been variable,29 30 so it is unclear if it is an effective intervention as part of 67 
an AMS programme. 68 
The purpose of this study was to conduct a feasibility study to determine if PCT testing is an effective 69 
and worthwhile intervention to introduce in a University Teaching Hospital to support the existing 70 
AMS programme and safely decrease antimicrobial prescribing in patients admitted with RTIs. 71 
 72 
Methods  73 
We conducted a single centre, randomised, open-label feasibility study of the introduction of PCT 74 
testing in patients admitted to hospital with a lower RTI under the care of the respiratory medicine 75 
team during on-call acute unselected general medical take to determine if PCT testing had an impact 76 
on antimicrobial consumption and patient’s length of stay (LOS) in hospital. The study was conducted 77 
in a single 321 bed inner city, voluntary acute University Teaching Hospital, which is part of the 78 
South/South West Hospital Group31 in the Republic of Ireland. It is a Model 3 (smaller general) 32 79 
hospital with a 24-hour emergency department, ICU and admits undifferentiated acute medical and 80 
surgical patients. The hospital has an established AMS programme and no significant changes were 81 
made to the AMS policies or programme during this study. 82 
Ethics 83 
The study was approved by the local ethics committee (approval code ECM 4 (w) and ECM 3 (III)). 84 
Written informed consent was obtained from all participants prior to study enrolment. 85 
Education and training 86 
The microbiology laboratory scientists received technical advice and training on the operation of the 87 
PCT assay from the manufacturer prior to study commencement. They also received a presentation 88 
on the introduction of PCT testing in the hospital.  89 
The respiratory medicine team received presentations at the respiratory journal club meetings and 90 
provision of written materials electronically. Presentations consisted of evidence supporting PCT use 91 
in practice, limitations of PCT testing, PCT measurement, and interpretation using a PCT-based 92 
antimicrobial prescribing algorithm (Supplementary material S1). Presentations were given prior to 93 
the study commencement and following medical staff rotation changes. The study protocol 94 
(Supplementary material S2), study flow chart and the PCT-based antimicrobial prescribing algorithm 95 
was provided to all physicians electronically.  96 
Recruitment and consent  97 
Inclusion criteria 98 
Adult patients ≥18 years of age, admitted to hospital under the care of the respiratory teams with an 99 
initial diagnosis of an acute lower RTI (i.e. Community acquired pneumonia 33 with severity defined by 100 
CURB-65 score34, Lower RTIs35, exacerbation of asthma36, COPD37, bronchiectasis38, interstitial lung 101 
disease39 and influenza35) and commenced on antimicrobial therapy were identified from the daily 102 
admission census or by the respiratory medicine teams.  103 
The randomisation process stratified patients according to presence or absence of severe COPD GOLD 104 
Stage D criteria 201737 to ensure balanced treatment allocation. Patients were then randomly 105 
allocated in a 2:1 ratio to either the PCT guided treatment group or the standard care respiratory 106 
control group. Randomisation was carried out using sequentially numbered opaque sealed envelopes. 107 
A second general control group of patients admitted under general medicine teams with a diagnosed 108 
acute lower RTI and received standard care (no PCT measurement) was recruited to provide a 109 
comparison of antimicrobial prescribing in RTIs by non-respiratory specialist physicians in the hospital. 110 
Exclusion Criteria 111 
Exclusion criteria were: unable to give written informed consent due to language restrictions, 112 
cognitive impairment or severe dementia; re-admission to hospital within 30 days of previous 113 
admission; immunosuppression (neutropenic, chemotherapy, radiation therapy or 114 
immunosuppressive therapy) other than corticosteroid use; life-threatening medical co-morbidities 115 
leading to possible imminent death, Do Not Resuscitate (DNR) status; patients with concurrent chronic 116 
infections necessitating prolonged antimicrobial treatment (cystic fibrosis, tuberculosis, infective 117 
endocarditis, osteo-articular infections, hepatic or cerebral abscesses, chronic prostatitis); patients 118 
with >24 hours of appropriate antimicrobial therapy prior to initial PCT level; active intravenous drug 119 
users; pregnant women. 120 
Intervention  121 
PCT testing was commenced in the microbiology department following completion of staff training 122 
and instrument validation. It was available during routine working hours (Monday to Friday, 9am-123 
5pm). PCT serum concentrations were measured using the VIDAS BRAHMS PCT (assay range 0.05-200 124 
µg/L) (Biomerieux, France). 125 
PCT serum concentrations were interpreted using an evidence based algorithm (Supplementary 126 
material S1)40 which has been validated in previous studies28 29 recommending antimicrobials strongly 127 
discouraged for PCT levels < 0.1 µg per litre, discouraged for levels 0.1 to 0.25 µg/L, encouraged for 128 
levels > 0.25 to 0.5 µg/L and strongly encouraged for levels > 0.5 µg/L. The algorithm also included 129 
specific overruling criteria where antimicrobials could be considered in the case of respiratory or 130 
haemodynamic instability; life-threatening co-morbidity; need for ICU admission; PCT < 0.1 µg /mL: 131 
CAP with CURB 65 > 3, COPD stage IV; PCT < 0.25 µg/mL: CAP with CURB 65 > 2; localised infection 132 
(abscess, empyema); immunocompromised (other than corticosteroids); concomitant infection in 133 
need of antimicrobials. 134 
The antimicrobial prescribing advice generated from the PCT algorithm was verbally communicated 135 
to the respiratory medicine team and this advice was non-binding. The respiratory medicine team 136 
retained prescribing autonomy regarding clinical decisions irrespective of the PCT level or algorithm 137 
generated antimicrobial prescribing advice. The algorithm adherence for antimicrobial prescribing 138 
recommendations was recorded at 24 hours following the PCT test for all patients along with the 139 
rational for prescribing decisions. Algorithm adherence was defined as antimicrobial therapy that was 140 
continued or discontinued in accordance with the PCT cut-off ranges. Non-adherence was defined as 141 
antimicrobial therapy that was not discontinued despite low PCT levels. Over-riding criteria were not 142 
considered when measuring adherence but were recorded as reasons for non-adherence. 143 
Patients were followed until their discharge. A further follow up of medical records took place at 30 144 
days post admission to identify re-admitted patients and re-admitted patients with infection re-lapse. 145 
Patient recruitment ran from June 1st 2017 to May 31st 2018. Figure 1 represents the patient hospital 146 
journey with a respiratory tract infection. 147 
Outcomes 148 
The primary outcomes were to quantify the individual inpatient antimicrobial consumption, 149 
prescription duration and the inpatient LOS. Following a recent systematic review which 150 
recommended that antimicrobial use should be expressed in at least two metrics simultaneously, 41 151 
antimicrobial consumption was measured using DDDs, days of therapy (DOTs) and prescription 152 
duration. DDDs were calculated using the Anatomical Therapeutic Chemical/Defined Daily Dose 153 
(ATC/DDD) index of the WHO Collaborating Centre for Drug Statistics Methodology 42 but were not 154 
adjusted for hospital activity. Days Of Therapy (DOT)43 calculates individual patient-days of 155 
antimicrobial exposure and accounts for dosing and frequency of each drug. Antimicrobial prescription 156 
duration was measured in days (defined as the number of days between the commencement and 157 
discontinuation of antimicrobials). The LOS was defined as date of discharge less date of admission.  158 
Secondary outcomes were number of infection and antimicrobial related adverse events during in-159 
patient LOS including mortality, hospital re-admission, and infection re-lapse requiring re-admission 160 
both within 30 days. Algorithm adherence for antimicrobial prescribing recommendations was 161 
measured.  162 
A qualitative process evaluation of the study was conducted in parallel with this feasibility study and 163 
will be reported in a subsequent paper. 164 
Statistical methods 165 
A Microsoft Access database (version 1903) was developed to record the study data. Statistical 166 
analysis was conducted using R (version 3.4.0) and was conducted on an intention to treat basis.  167 
The primary outcome of antimicrobial consumption between the PCT and respiratory control arms 168 
was evaluated using the non-parametric Wilcoxon Rank Sum test. A Kaplan-Meier curve was used to 169 
analyse the median time to discharge between the PCT and respiratory control group.    170 
Chi-square tests were used to evaluate differences between the PCT and respiratory control arms for 171 
all secondary outcomes - number of adverse events, re-admission and infection re-lapse requiring re-172 
admission both within 30 days. 173 
  174 
Results  175 
The respiratory medical teams admitted 823 general medical patients of whom 313 patients were 176 
classified as a respiratory infection or respiratory disorder during the recruitment period of June 1st 177 
2017 to May 31st 2018. A CONSORT flow diagram of recruitment can be seen in figure 2. 178 
A further 48 patients were recruited to the general control group. Three patients who were identified 179 
as suitable to enter the general control group were not recruited due to confusion, isolation due to 180 
infection and refused consent. 181 
Demographic data and study overview are contained in Table 1. Clinical findings of patients on 182 
admission to hospital are contained in Table 2. 183 
There were several differences between the baseline characteristics of the PCT group and respiratory 184 
control group. The PCT group contained more male patients (60% versus 42%), active smokers (25% 185 
versus 12.5%) and patients with pre-existing COPD A-C (29% versus 17%).    186 
There were a number of differences in final diagnosis between the PCT group and the respiratory 187 
control group with asthma (3.8% versus 15%), CAP (10% versus 7.5%), LRTI (30.4% versus 17.5%. CAP 188 
severity in the PCT group had CURB-65 scores ranging from 0 to 3 with a mean of 1.87 while the CAP 189 
severity in the respiratory control group had CURB-65 scores ranging from 0 to 1 with a mean of 0.66. 190 
The clinical findings on admission were similar between group with two exceptions where the PCT 191 
group had a higher percentage of patients who were productive of sputum on admission (49% versus 192 
37%) and patients prescribed antibiotics prior to admission (35% versus 25%).  193 
Procalcitonin testing and results 194 
The 79 patients randomised to the PCT group had a total of 163 PCT levels taken (median of 2 tests 195 
per patient (range 1-6). Overall the PCT levels had a median of 0.075µg/L (IQR 0.05 – 0.26). The initial 196 
PCT level was ≤0.24 µg/L for 58 patients (including 38 patients with an initial PCT level of ≤0.05 µg/L). 197 
Our primary outcome was to determine the inpatient antimicrobial consumption, duration of 198 
antimicrobial treatment and hospital LOS. The main outcomes can be seen in Table 3 and Figure 3. 199 
Statistical analysis was conducted on the PCT and respiratory control groups and does not include 200 
comparison with the general control group. 201 
There was no significant difference in antimicrobial exposure or usage per patient when measured 202 
as DDD (11.1 ± 7.5  versus 13.1 ± 10.7, p=0.218) (mean ± SD) or DOT (8.9 ± 6.3  versus 11 ± 7.6, 203 
p=0.077) of patients between the PCT and respiratory control group. Median values of both metrics 204 
DDD (8.66 versus 9.57) and DOT (7.5 versus 8.25) showed a decrease of 9% in antimicrobial 205 
consumption per patient. 206 
There was a significant difference in the antimicrobial duration in days between the PCT and 207 
respiratory control groups (median 7 versus 8 days, p=0.0125). There was also a significant 208 
difference between the PCT and respiratory control groups in the median LOS (p=0.009) and this can 209 
also be seen in the Kaplan–Meier curves in Figure 4. 210 
In the analysis of secondary outcomes there was no significant differences between the PCT and 211 
respiratory control groups in the incidence of adverse events during in-patient hospital stay 212 
(p=0.9852), the rate of hospital re-admission (p=0.1507), and the rate of infection re-lapse requiring 213 
re-admission both within 30 days (p=0.0924). 214 
Algorithm compliance is displayed in table 4.  215 
Overall PCT algorithm compliance per patient was 35% within 24 hours of PCT level being taken. 25 216 
patients had high PCT levels (≥ 0.25  µg/L) where the algorithm recommendation was to continue 217 
antimicrobial treatment and algorithm compliance was 100%. 67 patients had low PCT levels (< 0.25  218 
µg/L) where the algorithm recommendation was to discontinue antimicrobial treatment and 219 
algorithm compliance was low (10%). In these instances, the reasons for non-adherence were based 220 
on a clinical decision in 55/112 (49%) PCT levels with the remaining 57/112 (51%) PCT levels based on 221 
meeting various algorithm overriding criteria (respiratory or haemodynamic instability; life 222 
threatening co-morbidity; need for ICU admission; localised infection (abscess, empyema)).  223 
Seven patients had their antimicrobial treatment discontinued in compliance with the algorithm when 224 
PCT levels were low (< 0.25  µg/L). This resulted in shorter course lengths in five patients (< 7 days) 1 225 
course length completion as planned at 7 days, and early antimicrobial discontinuation (day 2) in a 226 
patient with influenzae. There were no hospital readmissions among these patients.  227 
In a further 9 patients where there was initial non-compliance with the algorithm recommendations 228 
when measured at 24 hours, their antimicrobial treatment was subsequently modified resulting in a 229 
shorter course length in 7 patients (< 7 days) and 2 further patients discontinued antimicrobials prior 230 
to discharge (1 patient re-admitted with infection).  231 
Algorithm compliance by indication was as follows; CAP (80%), asthma (50%) LRTI (30%), COPD (12.5%) 232 
and influenza virus (42%). PCT levels and algorithm compliance were found to be low in patients with 233 
COPD stage D and structural lung conditions like bronchiectasis and interstitial lung disease. In these 234 
cases, the clinical judgement of physicians was to over-ride the algorithm recommendations and 235 
continue antimicrobials.  236 
Microbiology positive specimens 237 
38 patients (23%) had positive microbiology results : 13 influenzae virus, 10 bacterial isolates from 238 
respiratory specimens and 7 yeast isolates from respiratory specimens. 239 
Adverse events 240 
Infection and antimicrobial related adverse events included gastro-intestinal (antimicrobial related 241 
diarrhoea 1 patient) renal function (acute kidney injury secondary to antimicrobials 1 patient), liver 242 
function (increased liver function tests secondary to antimicrobials 1 patient), respiratory disorders 243 
(hospital acquired pneumonia, hospital acquired influenzae, respiratory deterioration, 3 patients) and 244 
other events 2 patients. 245 
Mortality during the study 246 
Five patients included in the study died during their hospital stay, four from the PCT group and one 247 
from the respiratory control group (age range 75-94 years). All had multiple co-morbidities including 248 
cardiac (congestive cardiac failure, atrial fibrillation), renal and new or existing cancer diagnosis. 249 
Antimicrobial treatment decisions for these patients were based on clinical decisions.  250 
Discussion  251 
This feasibility study of the introduction of PCT testing has shown a positive effect on antimicrobial 252 
prescribing resulting in a decrease in the duration of antimicrobial courses in patients with RTIs and a 253 
decrease in LOS without an increase in adverse events or re-admission to hospital. The median 254 
duration of antimicrobial treatment was reduced from 8 to 7 days and antimicrobial consumption fell 255 
by 9% when measured as DDD and DOT. This study confirms the findings of previous PCT trials28 44 that 256 
it is an effective and worthwhile intervention to safely reduce antimicrobial exposure in patients with 257 
RTIs and supporting the AMS programme. However, there were several findings which may have 258 
influenced the outcomes and these need to be considered when viewing the overall results and 259 
considering progression to and design of a full randomised controlled trial (RCT). 260 
Overall PCT algorithm compliance was 35%, and compliance with stopping recommendations was 10% 261 
when PCT levels were low (<0.25 µg/L). The reasons for non-compliance were clinical judgement (49%) 262 
and meeting pre-determined over-riding criteria (51%). PCT was a new diagnostic test in the hospital 263 
and physicians can require time to become familiar with and develop confidence in the use of PCT 264 
testing.45 Other studies have found algorithm compliance can be variable ranging from 35% to 80%.44 265 
An international, multicentre study found that centres with experience of using PCT and ongoing 266 
reinforcement of PCT guided AMS had higher algorithm compliance than PCT naive centres.44 Protocol 267 
driven studies28 46 have also shown higher algorithm compliance and greater impact on antimicrobial 268 
prescriptions than studies taking a quality improvement implementation approach.29  269 
Algorithm compliance must improve significantly in a future trial to maximise the potential impact of 270 
PCT testing on antimicrobial prescribing decisions but also acknowledging the limitations of PCT and 271 
that physicians cannot rely on PCT alone to guide antibiotic therapy.23 In a future trial this should be 272 
addressed by a more comprehensive educational programme and more effective incorporation into 273 
the AMS programme to re-enforce PCT recommendations. Such an approach has been shown to be 274 
effective30 46 47 and required for interventions such as PCT to realise their full benefit.19 The educational 275 
element of this study may not have been sufficient. A future trial should consider the inclusion of more 276 
frequent educational presentations prior to and during the intervention and include case reviews of 277 
PCT patients. Consideration should be given to the development of pocket cards, incorporation into 278 
local electronic antimicrobial prescribing guidelines and availability of results on the hospital 279 
electronic laboratory system.46 280 
Delays in availability of PCT results may have also decreased the impact of the intervention and 281 
contributed to poor algorithm compliance with 38% of PCT serum results not available until the next 282 
day (24 hours after the serum sample was taken). This included results which were delayed or 283 
unavailable for 12 patients until after they were discharged. In a future trial prompt availability of PCT 284 
levels is important. This would allow physicians to consider PCT along with routine biochemistry and 285 
blood analysis, and the patients’ clinical parameters at the point of care when making antimicrobial 286 
prescribing decisions. Consideration should be given to measurement of algorithm adherence at 48 287 
hours to account for unforeseen delays PCT result availability or delayed physician review of PCT 288 
results. 289 
There were several factors involved in patient recruitment which may have influenced the primary 290 
outcomes of the study and should be addressed in a future trial design. These were the variation in 291 
infection severity between the PCT and respiratory control groups and the inclusion of patients who 292 
were already prescribed antimicrobials prior to hospital admission. These factors can be addressed in 293 
a suitably powered future RCT with the inclusion of illness severity scores, along with the use of 294 
multivariate and sub-group analysis. 295 
A future RCT would include a broader range of physicians rather than respiratory specialists alone. 296 
Antimicrobial consumption in the general control group of patients in this study was higher than in 297 
either of the respiratory groups. The addition of a PCT testing to the existing AMS programme may 298 
have the potential to have a greater impact on this patient group. 299 
 300 
Strengths and limitations 301 
The study was conducted in a setting where PCT  was a newly available test to physicians. A broad 302 
range of RTIs were recruited and the study took place over a calendar year and included seasonal 303 
variation in illness and prescribing. Patients were randomised to intervention or control, thus reducing 304 
selection bias. Serial PCT measurements were available to guide antimicrobial prescribing. 305 
The study had some limitations. The study population had a clinical need for antimicrobial treatment 306 
so the study was designed to examine the duration of therapy and LOS, rather than investigating the 307 
potential to withhold antimicrobial therapy. The study results may have been influence by a study 308 
effect. Both the PCT and respiratory control groups were treated by the same group of physicians who 309 
all received education and as they were aware that their behaviour was being monitored which may 310 
have resulted in a Hawthorn effect.48 The intervention was limited to one medical speciality which 311 
may limit its generalisability to other medical specialties and settings. The need for consent and PCT 312 
results which were not available at the point of clinical decision making in a small number of cases. 313 
 314 
Conclusion 315 
PCT testing had a positive effect on antimicrobial prescribing during this feasibility study. Several 316 
factors were identified which may have influenced the outcomes and the intervention 317 
implementation. The successful implementation of PCT testing requires an ongoing comprehensive 318 
education programme, greater integration into the AMS programme and delivery of PCT results in a 319 
timely manner. This feasibility study has shown that a larger randomised controlled trial would be 320 
beneficial to further explore the positive aspects of these findings.    321 
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RTI: Respiratory tract infection, PCT: procalcitonin, FBC: full blood count, U&E: urea and 512 
electrolytes  513 
Patient attends emergency 
department with a suspected RTI 
Routine diagnostic tests carried out of 
FBC and U&E, relevant microbiology 
specimens and chest X-ray if required 
On-call medical team review and 
admitted under their care with a 
provisional diagnosis of a RTI and 
commenced on antimicrobials 
 
Patient transferred to a ward in-
patient bed once available 
Regular (daily) medical review by 
admitting team of progress, diagnosis 
and treatment including antimicrobial 
therapy 
Routine blood tests carried out 
including FBC, U&E and microbiology, 
further radiological imaging if required 
Additional supportive treatment such 
as oxygen, chest physiotherapy, 
diagnostic procedures such as 
bronchoscopy performed where 
required 
Resolution of infection and discharge 
PCT levels measured on initial 
serum sample if the respiratory 
medicine team are on-call and 
patient recruited 
Antimicrobial prescribing advice 
determined using the PCT 
algorithm by the Consultant 
Microbiologist or Antimicrobial 
Pharmacist and communicated 
directly to the respiratory team 
once available 
PCT levels repeated at 
approximately 48-72 hours if   
patient remained in hospital, 
continued antimicrobial 
therapy, and where serum 
samples were available. 
 
 
Antimicrobial prescribing advice 
determined using the PCT 
algorithm by the Consultant 
Microbiologist or Antimicrobial 
Pharmacist and communicated 
directly to the respiratory team 
once available 
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Assessed for eligibility (n=313) 
Excluded (n=193) 
♦     Not meeting inclusion criteria         
(n=182) 
♦   Declined to participate (n=2) 
♦   Withdrew consent (n=1) 























167 (100%) 79 (47.3%) 40 (24.0%) 48 (28.7%) 
Gender Female 79 (47.3%) 31 (39.2%) 23 (57.5%) 25 (52.1%) 
  Male 88 (52.7%) 48 (60.8%) 17 (42.5%) 23 (47.9%) 
Age (years) 
  
68.7 ± 14 68.6 ± 13.6 68.4 ± 15.3 69.1 ± 13.9 
Co-existing conditions and risk factors 
Smoking Status Non-
smoker 
50 (30.3%) 26 (32.9%) 13 (32.5%) 11 (23.9%) 
  Smoker 33 (20%) 20 (25.3%) 5 (12.5%) 8 (17.4%) 
  Ex-smoker 82 (49.7%) 33 (41.8%) 22 (55%) 27 (58.7%) 
Asthma 28 (16.8%) 13 (16.5%) 10 (25%) 5 (10.4%) 
COPD A-C 58 (34.7%) 23 (29.1%) 10 (25%) 25 (52%) 
COPD D 24 (14.4%) 10 (12.7%) 5 (12.5%) 9 (18.8%) 
Bronchiectasis 16 (9.6%) 9 (11.4%) 3 (7.5%) 4 (8.3%) 
Interstitial lung disease  7 (4.2%) 4 (5%) 2 (5%) 1 (2.1%) 
Final diagnosis 
Asthma 11 (6.6%) 3 (3.8%) 6 (15%) 2 (4.2%) 
Community acquired pneumonia 18 (10.8%) 8 (10%) 3 (7.5%) 7 (14.6%) 
COPD 62 (37.1%) 24 (30.4%) 13 (32.5%) 25 (52%) 
Lower respiratory tract infection 45 (27%) 28 (35.4%) 7 (17.5%) 10 (20.8%) 
Other lower respiratory tract  
infections 
20 (12%) 10 (12.6%) 7 (17.5%) 3 (6.2%) 
Non-respiratory related 11 (6.6%) 6 (7.6%) 4 (10%) 1 (2.1%) 
 529 
  530 
Table 2. Clinical findings on admission to hospital* 531 
 
Total 
(n = 167) 
PCT 
(n = 79) 
Respiratory 
Control 
(n = 40) 
General control 
(n = 48) 
Respiratory rate- breaths/minute 22.1 ± 5 22.1 ± 5.4 21.1 ± 3.7 22.7 ± 5.2 
Systolic blood pressure- mmHg 133 ± 23.1 130.9 ± 22.9 136 ± 20.9 134 ± 25 
Diastolic blood pressure- mmHg 75 ± 14.1 74.8 ± 12 78.6 ± 14.8 72.3 ± 16.1 
Heart rate- beats/minute 91.8 ± 20.1 93.4 ± 23.3 91.2 ± 16.7 89.8 ± 16.7 
Temperature- °C 36.8 ± 0.8 36.8 ± 0.8 36.9 ± 0.8 36.8 ± 0.9 
Rigors - no. (%) 24 (14.4%) 11 (13.9%) 6 (15%) 7 (14.6%) 
Fever - no. (%) 18 (10.8%) 8 (10.1%) 5 (12.5%) 5 (10.4%) 
Chills - no. (%) 15 (9%) 10 (12.7%) 1 (2.5%) 4 (8.3%) 
Number of clinical signs of infection  1.8 ± 1.3 1.9 ± 1.3 1.7 ± 1.2 1.8 ± 1.3 
 
Documented signs of respiratory illness 
Cough - no. (%)  132 (79%) 64 (81%) 31 (77.5%) 37 (77%) 
Shortness of breath - no. (%) 101 (60.5%) 45 (57%) 23 (57.5%) 33 (68.7%) 
Productive of sputum - no. (%) 81 (48.5%) 39 (49.4%) 15 (37.5%) 27 (56.2%) 
Dyspnoea - no. (%) 49 (29.3%) 22 (27.8%) 10 (25%) 17 (35.4%) 
Pleuritic pain - no. (%) 26 (15.6%) 10 (12.7%) 9 (22.5%) 7 (14.6%) 
Respiratory failure - no. (%) 19 (11.4%) 8 (10.1%) 5 (12.5%) 6 (12.5%) 
Abnormal chest exam - no. (%) 144 (86.2%) 70 (88.6%) 31 (77.5%) 43 (89.6%) 
Abnormal radiological findings - no. (%) 94 (56.3%) 42 (53.2%) 21 (52.5%) 28 (58.3%) 
CURB-65 score (CAP patients) 1.56 ± 1.05 1.87 ± 1.05 0.66 ± 0.47 1.57 ± 1.05 
Number of signs of acute respiratory 
illness 
3.9 ± 1.4 3.8 ± 1.4 3.8 ± 1.4 4 ± 1.3 
 
Antimicrobials prescribed pre-
admission - no. (%) 
59 (35.3%) 28 (35.4%) 10 (25%) 21 (43.7%) 
Corticosteroids prescribed pre-
admission - no. (%) 
34 (20.4%) 14 (17.7%) 7 (17.5%) 13 (27%) 
Infection source 
Community - no. (%) 149 (89.2%) 70 (88.6%) 32 (80%) 47 (98%) 
Healthcare - no. (%) 13 (7.8%) 6 (7.6%) 6 (15%) 1 (2%) 
Hospital - no. (%) 5 (3%) 3 (3.8%) 2 (5%) 0 (0%) 
*plus minus values are means + SD  532 
Table 3. Primary and secondary outcome data 533 
Primary outcomes  
 Mean ± SD  
(Median) 
PCT 
(n = 79) 
Respiratory Control 
(n = 40) 
General control 
(n = 48) 
p value 
Defined daily doses 
per patient 
11.1 ± 7.5 
(8.66) 
13.1 ± 10.7 
(9.57) 
18.5 ± 11 
(16.5) 
0.218 
Days of therapy per 
patient 
8.9 ± 6.3 
(7.5) 
11 ± 7.6 
(8.25) 
13.7 ± 11.1 
(11.63) 
0.077 




6.8 ± 2.8 
(7) 
8.9 ± 4 
(8) 
8.4 ± 3.6 
(8) 
0.0125* 
Length of hospital 
stay (days) 
7.4 ± 4.3 
(7) 
10.5 ± 6.1 
(8) 








7 (8.9%) 8 (20%) 7 (14.6%) 0.1507 
Relapse of infection 
within 30 days 
6 (7.6%) 8 (20%) 6 (12.5%) 0.0924 
Adverse events 6 (7.6%) 3 (7.5%) 4 (8.3%) 0.9852 
*= statistical significance was set as <0.05, p-values relate to the comparison between the PCT and 534 
respiratory control groups 535 
 536 
 537 
Figure 3. Main antimicrobial consumption outcomes. 538 
  539 
 540 
 541 
Figure 4. Comparison of time to discharge probability for PCT versus respiratory control arms-542 
Kaplan–Meier curves. Median probability of discharge is given by the horizontal dashed line. 543 
  544 





































25 44 25 0 100% 
 546 
